Denali Therapeutics Secures Landmark FDA Approval for Hunter Syndrome Drug

Denali Therapeutics gains FDA accelerated approval for AVLAYAH, a novel brain-penetrating therapy for Hunter syndrome, sending its stock up 10.5% to a new high.

In a significant regulatory achievement, Denali Therapeutics has obtained accelerated approval from the U.S. Food and Drug Administration (FDA) for its therapy, AVLAYAH. This marks the first new treatment option for Hunter syndrome, also known as Mucopolysaccharidosis type II (MPS II), to emerge in nearly twenty years. The therapy is distinguished by its novel receptor-mediated technology designed to cross the blood-brain barrier, a historic first for enzyme replacement treatments targeting this condition.

Financial and Market Response

The market reacted positively to the announcement, with Denali's shares advancing approximately 10.5 percent to reach €20.00, establishing a new 52-week high. The company's financial position appears robust enough to support its ongoing pipeline development. As of the end of 2025, Denali reported strong liquidity, holding about $966 million in cash and equivalents with minimal debt, despite substantial research and development expenditures.

Market sentiment is reflected in analyst ratings and ownership:
* Consensus Recommendation: Strong Buy
* Average Price Target: $32.93
* Institutional Ownership: Approximately 92.92%

The high level of institutional investment underscores confidence in Denali's broader technology platform, which includes programs targeting Parkinson's and Alzheimer's diseases alongside Hunter syndrome.

Addressing a Rare Disease with Neurological Impact

The FDA's decision was grounded in compelling biomarker data from clinical trials. The therapy demonstrated a reduction in heparan sulfate concentration in patients' cerebrospinal fluid by an average of 91 percent through week 24. Furthermore, 93 percent of trial participants saw their levels return to the normal range. By successfully delivering enzyme replacement directly to the brain, AVLAYAH addresses the neurological symptoms of Hunter syndrome, which were previously considered largely untreatable.

This accelerated approval, however, is contingent upon the verification of clinical benefit in the ongoing Phase 2/3 COMPASS study. A key question remains whether the dramatic reduction in heparan sulfate biomarkers will conclusively translate into long-term clinical outcomes for patients. Success in confirming these benefits will be crucial for converting the conditional approval into a full, permanent marketing authorization. As part of the approval process, Denali also received a valuable Priority Review Voucher for rare pediatric diseases.

The focus now shifts squarely to the results of the COMPASS trial, which will ultimately determine the long-term commercial future of AVLAYAH.